文献速递脑血管病

卒中症状作为卒中一级预防试验的替代终点:CREST研究的经验

Stroke Symptoms as a Surrogate in Stroke Primary Prevention Trials: The CREST Experience.
PubMed 文献 · Neurology · 2022-08-26

该研究对CREST试验中826例基线无卒中症状的无症状患者进行事后分析,比较颈动脉支架置入术(CAS)与颈动脉内膜切除术(CEA)在裁定卒中、新发卒中症状及复合终点上的差异。结果显示CAS较CEA的裁定卒中风险无显著差异(HR 1.02,95%CI 0.57-1.85),但新发卒中症状风险(HR 1.54,95%CI 1.15-2.08)及复合终点风险(HR 1.38,95%CI 1.04-1.83)均显著升高。作者提出将新发卒中症状等替代事件纳入一级预防试验终点可提高试验可行性。

要点

  • 在基线无卒中症状的无症状患者中,CAS较CEA的裁定卒中风险无显著差异(HR 1.02,95%CI 0.57-1.85)。
  • CAS较CEA的新发卒中症状风险显著升高(HR 1.54,95%CI 1.15-2.08)。
  • CAS较CEA的裁定卒中或新发症状复合终点风险显著升高(HR 1.38,95%CI 1.04-1.83)。

核心结论

  • 将新发卒中症状作为替代终点使事件数增加超过4倍,并显示CAS较CEA的脑血管风险存在此前未报道的显著差异。
  • 作者提出,将新发卒中症状等替代事件纳入卒中一级预防试验的终点可使试验更可行。

研究设计与样本

  • 多中心随机对照试验CREST的事后分析,纳入826例基线无卒中症状的无症状患者。
  • CREST使用无卒中状态验证问卷(QVSS)在基线和随访时评估卒中症状。
  • 本分析要求基线无卒中症状,裁定卒中定义与CREST主分析相同,新发卒中症状定义为随访中出现≥1个卒中症状。
  • 比较CAS与CEA在裁定卒中、卒中症状及裁定卒中或卒中症状复合终点上的治疗差异。

主要发现

  • 裁定卒中事件发生于44例患者,新发卒中症状发生于183例患者。
  • CAS较CEA的裁定卒中风险无显著差异(HR 1.02,95%CI 0.57-1.85)。
  • CAS较CEA的新发卒中症状风险显著升高(HR 1.54,95%CI 1.15-2.08)。
  • CAS较CEA的裁定卒中或新发症状复合终点风险显著升高(HR 1.38,95%CI 1.04-1.83)。

关键数值与推荐

  • 无症状患者卒中事件率低,使CAS与CEA治疗差异的评估具有挑战性。
  • 将新发卒中症状作为替代终点使事件数增加超过4倍。

临床怎么用

  • 作者提出,将新发卒中症状等替代事件纳入卒中一级预防试验的终点可使试验更可行。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The use of surrogate end points can decrease sample size while maintaining statistical power. This report considers incident stroke symptoms as a surrogate end point in a post hoc analysis of asymptomatic patients from the multicenter, randomized Carotid Revascularization Endarterectomy vs Stenting Trial (CREST). METHODS: CREST assessed stroke symptoms using the Questionnaire for Verifying Stroke-free Status (QVSS) at baseline and follow-up. While the primary analysis of CREST defined "asymptomatic" as having been free of stroke/transient ischemic attack for 180 days, herein the population was further restricted by requiring no stroke symptoms at baseline. Incident adjudicated stroke was defined the same as for the primary analysis; incident stroke symptoms was defined as developing ≥1 stroke symptom in follow-up. Treatment differences between stenting (CAS) and endarterectomy (CEA) were assessed for 3 end points: adjudicated stroke, stroke symptoms, and adjudicated stroke or stroke symptoms. RESULTS: The cohort included 826 of the 1,181 asymptomatic patients in CREST. Adjudicated stroke events occurred in 44 patients, and incident stroke symptoms occurred in 183. Analysis of adjudicated stroke end points demonstrated a nonsignificant hazard ratio (HR) for CAS compared with CEA of 1.02 (95% CI 0.57-1.85). The corresponding HR for the incident stroke symptoms outcome was 1.54 (95% CI 1.15-2.08), and the HR for the composite outcome of adjudicated stroke or incident symptoms was 1.38 (95% CI 1.04-1.83), both significant. DISCUSSION: The low stroke event rates in asymptomatic patients challenges the assessment of CAS-versus-CEA treatment differences. Incorporating incident stroke symptoms as a surrogate outcome increased the number of events by over 4-fold. The analysis demonstrated a previously unreported significant difference in cerebrovascular risk with CAS compared with CEA. We propose that broadening the end points of primary stroke prevention trials to include surrogate events such as incident stroke symptoms could make trials more feasible.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Meschia JF, Brott TG, Voeks J, et al. Stroke Symptoms as a Surrogate in Stroke Primary Prevention Trials: The CREST Experience. Neurology. 2022. PMID: 36028326. doi:10.1212/WNL.0000000000201188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。